Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 10;13(6):1422.
doi: 10.3390/biomedicines13061422.

Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation

Affiliations
Review

Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation

Ao Liu et al. Biomedicines. .

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a global health burden, however, therapeutic advancements remain hindered by incomplete insights on mechanisms and suboptimal clinical interventions. This review focused on the transcription factors (TFs) associated with the gut-liver axis, emphasizing their roles as molecular interpreters of systemic crosstalk in MAFLD. We delineate how TF networks integrate metabolic, immune, and gut microbial signals to manage hepatic steatosis, inflammation, and fibrosis. For instance, metabolic TFs such as peroxisome proliferator-activated receptor α (PPARα) and farnesoid X receptor (FXR) are responsible for regulating lipid oxidation and bile acid homeostasis, while immune-related TFs like signal transducer and activator of transcription 3 (STAT3) modulate inflammatory cascades involving immune cells. Emerging evidence highlights microbiota-responsive TFs, like hypoxia-inducible factor 2α (HIF2α) and aryl hydrocarbon receptor (AHR), linking microbial metabolite signaling to hepatic metabolic reprogramming. Critically, TF-centric therapeutic strategies, including selective TF-agonists, small molecules targeted to degrade TF, and microbiota modulation, hold considerable promise for treating MAFLD. By synthesizing these insights, this review underscores the necessity to dissect TF-mediated interorgan communication and proposes a roadmap for translating mechanism discoveries into precision therapies. Future research should prioritize the use of multi-omics approaches to map TF interactions and validate their clinical relevance to MAFLD.

Keywords: inflammation; metabolic dysfunction-associated fatty liver disease; metabolism; microbiota; molecular mechanisms; transcription factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Metabolism-related TFs in MAFLD. Green text suggests beneficial effects on MAFLD, while red text suggests harmful effects on MAFLD.
Figure 2
Figure 2
Inflammation and immune-related TFs in MAFLD. Green text suggests beneficial effects on MAFLD, while red text suggests harmful effects on MAFLD.
Figure 3
Figure 3
Microbiota and metabolite-related TFs in MAFLD. Green text suggests beneficial effects on MAFLD, while red text suggests harmful effects on MAFLD.

Similar articles

References

    1. Le M.H., Yeo Y.H., Li X., Li J., Zou B., Wu Y., Ye Q., Huang D.Q., Zhao C., Zhang J., et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2022;20:2809–2817.e28. doi: 10.1016/j.cgh.2021.12.002. - DOI - PubMed
    1. Zhou J., Zhou F., Wang W., Zhang X.J., Ji Y.X., Zhang P., She Z.G., Zhu L., Cai J., Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851–1864. doi: 10.1002/hep.31150. - DOI - PubMed
    1. Sheka A.C., Adeyi O., Thompson J., Hameed B., Crawford P.A., Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175–1183. doi: 10.1001/jama.2020.2298. - DOI - PubMed
    1. Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77:1335–1347. doi: 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed
    1. Lei Y., Tang L., Chen Q., Wu L., He W., Tu D., Wang S., Chen Y., Liu S., Xie Z., et al. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat. Commun. 2022;13:6862. doi: 10.1038/s41467-022-34671-1. - DOI - PMC - PubMed

LinkOut - more resources